VERU INC. filed this 10-K on 20181213

Document Outline
Entire Document (5.6 MB)
Subdocument - 10-K - 10-K
  Page 1 - UNITED STATES
  Page 2 - N/A
  Page 3 - N/A
  Page 4 - N/A
  Page 5 - General
  Page 6 - Company History
  Page 7 - Products
  Page 8 - VERU 944 (zuclomiphene citrate) for the treatment of hot flashes caused by prostate cancer hormonal
  Page 9 - VERU-111, an oral, next generation, first-in-class small molecule for the treatment of metastatic pr
  Page 10 - Market.
  Page 11 - Market.
  Page 12 - Development Plan.
  Page 13 - U.S. Market
  Page 14 - Market.
  Page 15 - FDA Regulation of Pharmaceutical Products.
  Page 16 - 505(b)(2) Approval Process.
  Page 17 - Post Approval Requirements for Pharmaceutical Products.
  Page 18 - N/A
  Page 19 - Anti-Corruption Laws.
  Page 20 - VERU-111 License.
  Page 21 - Significant Customers
  Page 22 - Competition
  Page 23 - Backlog
  Page 24 - Risks Related to the Regulation and Commercialization of Our Products and Drug Candidates
  Page 25 - We could experience delays in our planned clinical trials.
  Page 26 - We may be subject to risks relating to collaboration with third parties.
  Page 27 - We expect to rely on third party manufacturers for our drug candidates.
  Page 28 - We may fail to commercialize our drug candidates.
  Page 29 - We could experience misconduct by our employees.
  Page 30 - Our drug products may be subject to governmental pricing controls.
  Page 31 - If we fail to obtain additional capital, we may need to reduce the scope of our development programs
  Page 32 - The FDA recently issued a final order reclassifying female condoms as Class II medical devices, whic
  Page 33 - We may not be able to sustain price levels for sales of FC2 in the U.S. market.
  Page 34 - Since we sell FC2 in foreign markets, we are subject to international business risks that could adve
  Page 35 - Material adverse or unforeseen legal judgments, fines, penalties, or settlements could have an adver
  Page 36 - Any failure to comply with the FCPA and similar anti-bribery laws in non-U.S. jurisdiction could mat
  Page 37 - Our credit agreement contains debt covenants which restrict our current and future operations, inclu
  Page 38 - Risks Relating to Our Intellectual Property
  Page 39 - If some or all of our or our licensor s patents expire or are invalidated or are found to be unenfor
  Page 40 - We have continuing obligations under our purchase agreements to acquire the intellectual property ri
  Page 41 - We must submit patent certifications in connection with the 505(b)(2) FDA regulatory pathway.
  Page 42 - We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secre
  Page 43 - Risks Related to Ownership of Our Common Stock
  Page 44 - We are a "smaller reporting company" and will be able to avail ourselves of reduced disclosure requi
  Page 45 - If our stock price declines, our common stock may be subject to delisting from the NASDAQ Capital Ma
  Page 46 - N/A
  Page 47 - N/A
  Page 48 - N/A
  Page 49 - N/A
  Page 50 - Overview
  Page 51 - N/A
  Page 52 - Revenues
  Page 53 - Results of Operations
  Page 54 - Liquidity and Sources of Capital
  Page 55 - Operating activities
  Page 56 - SWK Credit Agreement
  Page 57 - Critical Accounting Estimates
  Page 58 - Fair Value Measurements
  Page 59 - Impact of Inflation and Changing Prices
  Page 60 - N/A
  Page 61 - N/A
  Page 62 - N/A
  Page 63 - 1.Financial Statements
  Page 64 - 3.Exhibits
  Page 65 - N/A
  Page 66 - N/A
  Page 67 - N/A
  Page 68 - N/A
  Page 69 - Index to Consolidated Financial Statements
  Page 70 - Report of Independent Registered Public Accounting Firm
  Page 71 - N/A
  Page 72 - N/A
  Page 73 - N/A
  Page 74 - N/A
  Page 75 - Note 1 Nature of Business and Significant Accounting Policies
  Page 76 - Fixed assets:
  Page 77 - Goodwill
  Page 78 - Unearned revenue
  Page 79 - Advertising
  Page 80 - Recently Issued Accounting Pronouncements
  Page 81 - Business Combinations (Topic 805): Clarifying the Definition of a Business
  Page 82 - N/A
  Page 83 - N/A
  Page 84 - Note 3 Fair Value Measurements
  Page 85 - Note 4 Accounts Receivable and Concentration of Credit Risk
  Page 86 - Note 5 Inventory
  Page 87 - Intangible Assets
  Page 88 - Note 7 Debt
  Page 89 - N/A
  Page 90 - Revolving Line of Credit
  Page 91 - Aspire Capital Purchase Agreement
  Page 92 - Common Stock Offering
  Page 93 - Restricted Stock
  Page 94 - Restricted Stock Units
  Page 95 - Note 11 Contingent Liabilities
  Page 96 - License and Purchase Agreements
  Page 97 - N/A
  Page 98 - N/A
  Page 99 - Note 13 Net Loss Per Share
  Page 100 - Note 14 Industry Segments and Financial Information about Foreign and Domestic Operations
  Page 101 - Note 16 Related Party Transactions
Subdocument - EX-10.13 - EX-10.13
  Page 1 - Exhibit 10.13
  Page 2 - Equity Awards.
  Page 3 - Termination by the Company Without Cause or by the Executive for Good Reason
  Page 4 - Death or Disability
  Page 5 - Change in Control Termination
  Page 6 - Section 280G
  Page 7 - Company Creation and Use of Confidential Information
  Page 8 - Non-competition
  Page 9 - Non-interference with Other Business Relationships
  Page 10 - Work Made for Hire; Assignment
  Page 11 - Governing Law; Jurisdiction and Venue
  Page 12 - Reimbursements
  Page 13 - Withholding
Subdocument - EX-10.32 - EX-10.32
  Page 1 - Exhibit 10.32
  Page 2 - N/A
  Page 3 - N/A
  Page 4 - N/A
  Page 5 - N/A
  Page 6 - N/A
  Page 7 - N/A
  Page 8 - N/A
  Page 9 - N/A
  Page 10 - N/A
  Page 11 - N/A
  Page 12 - N/A
Subdocument - EX-21 - EX-21
  Page 1 - N/A
Subdocument - EX-23.1 - EX-23.1
  Page 1 - N/A
Subdocument - EX-31.1 - EX-31.1
  Page 1 - N/A
Subdocument - EX-31.2 - EX-31.2
  Page 1 - N/A
Subdocument - EX-32.1 - EX-32.1
  Page 1 - N/A